Ipsen S.A. (OTCMKTS:IPSEY – Get Free Report)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $30.20 and traded as high as $31.34. Ipsen shares last traded at $30.02, with a volume of 775 shares traded.
Ipsen Stock Performance
The business has a 50 day moving average of $29.31 and a 200 day moving average of $30.20.
Ipsen Company Profile
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Further Reading
- Five stocks we like better than Ipsen
- How to Calculate Inflation Rate
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Canadian Penny Stocks: Can They Make You Rich?
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to buy stock: A step-by-step guide for beginners
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.